

## 12 PLASMA DERIVED BLOOD COMPONENTS

Date Issued: January 2005  
Date Revised: July 2011  
Review Date: July 2013  
Authorised by: KEMH Transfusion Committee  
Review Team: KEMH Transfusion Committee

12.15 CMV immunoglobulin  
Section 12  
Transfusion Medicine Protocols  
Women's & Newborn Health Services  
Perth Western Australia

### 12.15 CMV IMMUNOGLOBULIN VF (1.5 MILLION UNITS)

#### DESCRIPTION

Each vial contains 60mg/mL human plasma proteins, with 98% being immunoglobulins (mainly IgG) and contains 1.5 million units of CMV Immunoglobulin activity. This product is for intravenous use.

#### INDICATIONS

- Prevention of CMV infection in bone marrow, cardiac and liver transplant recipients who are CMV antibody negative where the donor is CMV antibody positive.
- Treatment of established CMV infection in association with virucidal treatment.

#### DOSE AND ADMINISTRATION

No agreed dosage is standard. Dosage varies depending on the clinical indication. Refer to Consultant Immunologist or Haematologist for advice.

- The product must be used immediately after opening. Any unused solution must be discarded. Do not use the product if it appears turbid or cloudy.
- Allow the product to reach room temperature before administration.
- Administer Intravenously only.
- Commence the infusion at a rate of 1mL per minute.
- After 15 minutes the rate may gradually be increased to a maximum of 3 to 4mLs per minute over a further 15 minutes.

**Refer to current product information sheet for further details of compatibility with other medicines and to view Table of CMV Immunoglobulin VF Dosage based on bodyweight recommendations. (See link below)**

[http://www.csl.com.au/s1/cs/auhq/1217017237558/Web\\_Product\\_C/1196562707049/ProductDetail.htm](http://www.csl.com.au/s1/cs/auhq/1217017237558/Web_Product_C/1196562707049/ProductDetail.htm)

## PATIENT MONITORING

Reactions are often related to the infusion rate and most likely to occur within the first hour of infusion.

Mild pyrexia, abdominal pain, headache, chest tightness skin rash nausea or vomiting have been reported after injection of Immunoglobulin.

Refer severe reactions to the Consultant Haematologist unless the patient is under the care of the PMH Department of Immunology in which case refer to the Consultant Immunologist

Take observations as for all blood products

- Baseline TPR and BP
- TP at 15 minutes then hourly until completion.
- TPR and BP on completion.

## DOCUMENTATION

A record should be kept in the patient's history of the following

- The date of infusion
- Patients observations and general condition during the infusion
- Amount given
- The batch number and expiry date of each bottle used (place a sticker with the batch number on the Transfusion Medicine Record sheet PMH MR616/ KEMH MR735). This information is important should the patient have a reaction to the infusion or if there is a need to trace recipients of certain batch numbers at a later date.